Earnings History Data for Novartis AG (NVS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Novartis AG

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
31-01-2024	PM		NVS	Novartis	227,136	1.53	1.67	0.00	Novartis Non-GAAP EPS of $1.53 misses by $0.13, revenue of $11.42B misses by $350M [1/31/2024 5:19 AM]	103.53	-4.22 (-3.91%)	105.68	-2.07 (-1.92%)	75.68 - 108.78	3,001,374	1,150,000	149,400
Novartis FY 2023 Earnings Preview [1/30/2024 11:18 AM] Novartis Non-GAAP EPS of $1.53 misses by $0.13, revenue of $11.42B misses by $350M [1/31/2024 5:19 AM] Novartis dips after Q4 results miss estimates, dividend raise proposed [1/31/2024 6:12 AM] Biggest stock movers today: Plug Power, Paramount Global, Google parent Alphabet, and more [1/31/2024 9:46 AM]
24-10-2023	PM		NVS	Novartis AG	200,680	1.74	1.71	1.58	Novartis reports Q3 earnings boosted by strong sales of key drugs and raises FY23 outlook [10/24/2023 1:31 AM]	94.94	0.25 (0.26%)	94.39	-0.30 (-0.32%)	73.14 - 99.94	2,227,613	1,830,000	208,832
Novartis reports Q3 earnings boosted by strong sales of key drugs and raises FY23 outlook [10/24/2023 1:31 AM] Novartis Q3 2023 Earnings Preview [10/23/2023 11:39 AM]
18-07-2023	PM	0:00 AM ET (Jul 18)	NVS	Novartis AG	208,420	1.83	1.67	1.56	Novartis looks to third straight quarterly EPS beat [7/17/2023 2:54 PM]	103.39	4.45 (4.50%)	101.73	2.79 (2.82%)	74.09 - 105.56	4,901,033	2,200,000	90,356
Novartis looks to third straight quarterly EPS beat [7/17/2023 2:54 PM] Novartis posts Q2 earnings beat, raises FY23 outlook; board endorses Sandoz spinoff [7/18/2023 3:27 AM] Inside Novartis: Entresto, Cosentyx drive sales higher [7/18/2023 8:50 AM]
25-04-2023	PM	0:00 AM ET (Apr 25)	NVS	Novartis AG	208,990	1.71	1.56	1.46	Novartis beats Q1 top and bottom line estimates; raises FY23 outlook & planned spin-off on track for H2 [4/25/2023 1:05 AM]	103.91	3.32 (3.30%)	104.82	4.23 (4.21%)	74.09 - 105.56	3,653,649	1,820,000	58,174
Novartis beats Q1 top and bottom line estimates; raises FY23 outlook & planned spin-off on track for H2 [4/25/2023 1:05 AM] Novartis hits 52-week high as Wall Street awaits Q1 2023 earnings [4/24/2023 12:22 PM] Novartis trades higher as Entresto, new drugs drive Q1 revenue, raises FY23 outlook [4/25/2023 4:58 AM] Hot Stocks: Earnings sparked movement in PEP, JBLU, NVS, MCD, BIIB and HAL [4/25/2023 1:10 PM]
01-02-2023	PM	0:00 AM ET (Feb 1)	NVS	Novartis AG	192,820	1.51	1.42	1.40	Novartis reports mixed Q4 earnings, continue to grow with further core margin expansion; initiates FY23 guidance [2/1/2023 1:17 AM]	88.21	-2.41 (-2.66%)	88.08	-2.54 (-2.80%)	74.09 - 94.26	2,760,399	2,130,000	183,419
Novartis reports mixed Q4 earnings, continue to grow with further core margin expansion; initiates FY23 guidance [2/1/2023 1:17 AM] What to expect from Novartis Q4 earnings? [1/31/2023 11:37 AM] Novartis trades lower as Q4 sales dip amid dollar impact; provides FY23 outlook [2/1/2023 5:57 AM] Novartis proposes dividend raise to CHF 3.20 [2/1/2023 7:45 AM] Novartis ends plans to develop Cosentyx for another autoimmune condition [2/1/2023 12:20 PM]
25-10-2022	PM	5:00 AM ET (Oct 25)	NVS	Novartis AG	168,290	1.58	1.57	1.71		78.49	0.78 (1.00%)	77.72	0.01 (0.01%)	74.09 - 94.26	2,276,460	2,230,000	76,503
Novartis delivers solid Q3 performance; reaffirms FY22 soft guidance [10/25/2022 3:49 AM] Sandoz spin-off updates, comments on Gilenya generics in focus for Novartis Q3 earnings [10/24/2022 3:16 PM] Novartis iptacopan beats AstraZeneca's Soliris/Ultomiris to treat rare blood disorder in trial [10/24/2022 6:03 AM] Novartis Q3 earnings fall amid strong dollar impact; reaffirms FY22 outlook [10/25/2022 6:01 AM] UPDATE 1-Novartis earnings slip 4% on strong dollar, Gilenya competition [Oct-25-22 01:35AM] Novartis earnings slip 4% on strong dollar, Gilenya competition [Oct-25-22 01:19AM] Novartis maintains growth momentum and confirms FY22 Group guidance [Oct-25-22 01:00AM] Novartis Experimental Drug Shows Meaningful Superiority Over Previous Treatment In Rare Blood Disorder [Oct-24-22 06:59AM] Novartis hemoglobinuria trial meets two primary endpoints [Oct-24-22 02:27AM] Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study [Oct-24-22 01:15AM]
19-07-2022	PM	0:00 AM ET (Jul 19)	NVS	Novartis AG	187,270	1.56	1.51	1.64	Novartis Non-GAAP EPS of $1.56 beats by $0.01, revenue of $12.78B beats by $40M [7/19/2022 3:45 AM]	85.98	3.28 (3.97%)	86.00	3.30 (3.99%)	79.09 - 95.17	2,270,967	2,210,000	15,026
Novartis Non-GAAP EPS of $1.56 beats by $0.01, revenue of $12.78B beats by $40M [7/19/2022 3:45 AM] All eyes on Novartis Q2 show amid likely impact from strong dollar [7/18/2022 11:58 AM] Novartis Q2 core earnings rise Y/Y, reaffirms FY22 outlook; Sandoz review "on track" [7/19/2022 5:15 AM] UPDATE 2-Novartis expects improved earnings at generics unit Sandoz [Jul-19-22 01:36AM] Novartis expects improved earnings at generics unit Sandoz [Jul-19-22 01:17AM] Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY22 Group guidance [Jul-19-22 01:00AM]
26-04-2022	PM	5:00 AM ET (Apr 26)	NVS	Novartis	201,195	1.46	1.44	0.00	Novartis Non-GAAP EPS of $1.46 misses by $0.05, revenue of $12.53B misses by $80M [4/26/2022 5:35 AM]	89.03	-1.41 (-1.55%)	90.20	-0.24 (-0.27%)	79.09 - 95.17	2,093,620	2,400,000	201,823
Will Novartis Q1 result bring positive surprise amid pricing pressure in generic drug unit [4/25/2022 11:48 AM] Novartis Q1 sales rise on the back of Sandoz unit, confirms FY22 outlook; hires analyst to drive growth/strategy [4/26/2022 5:17 AM] Novartis Non-GAAP EPS of $1.46 misses by $0.05, revenue of $12.53B misses by $80M [4/26/2022 5:35 AM] Novartis earnings edge higher on Cosentyx, Entresto sales [Apr-26-22 01:24AM] Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook [Apr-26-22 01:00AM] Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug [Apr-25-22 01:16PM] Novartis income edges higher on strong Sandoz, Entresto [Apr-26-22 01:24AM] Novartis CEO on First-Quarter Earnings, Drugs Pipeline [Apr-26-22 03:15AM] Novartis Earnings Get Boost From Sales of Key Drugs [Apr-26-22 04:36AM] Novartis Earnings Get a Boost From Sales of Its Key Drugs [Apr-26-22 04:36AM] Here's The Surprising Source Of Novartis' First-Quarter Sales Growth [Apr-26-22 09:18AM] Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook [Apr-26-22 06:49AM] Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth [Apr-26-22 10:15AM] Novartis (NVS) Q1 2022 Earnings Call Transcript [Apr-26-22 05:30PM]
02-02-2022	PM	0:00 AM ET (Feb 2)	NVS	Novartis AG	192,190	1.40	1.44	1.34	Novartis Q4 Non-GAAP EPS of $1.40 misses by $0.01, revenue of $13.23B misses by $20M [2/2/2022 2:04 AM]	85.88	-2.31 (-2.61%)	85.10	-3.08 (-3.49%)	79.34 - 95.17	4,119,475	2,820,000	118,000
Will Novartis Q4 results bring positive surprise amid buzz surrounding Sandoz? [2/1/2022 11:20 AM] Blackstone, Carlyle said to consider joint bid for Novartis generics business [2/1/2022 10:15 AM] Novartis Q4 Non-GAAP EPS of $1.40 misses by $0.01, revenue of $13.23B misses by $20M [2/2/2022 2:04 AM] Novartis down 2% as Q4 trail estimates; Entresto, Zolgensma Cosentyx record robust growth [2/2/2022 4:17 AM] Polaris Capital Management, LLC Buys FedEx Corp, Allison Transmission Holdings Inc, Wabash ... [Feb-01-22 05:38PM] Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report [Feb-01-22 02:54PM] Blackstone, Carlyle Mull Joint Bid for Novartis Generics Arm [Feb-01-22 02:42PM] Blackstone, Carlyle consider joint bid for Novartis generics unit - Bloomberg News [Feb-01-22 10:16AM] Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO [Feb-01-22 09:45AM] Novartis forecasts 2022 sales and profit growth; Sandoz review continues [Feb-02-22 01:18AM] Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021 [Feb-02-22 01:00AM] Novartis sees steady growth as weighs selling generics arm [Feb-02-22 01:18AM] Novartis Earnings Rise, Says Review of Sandoz Unit Progressing [Feb-02-22 06:14AM] Novartis Says Sandoz Future Uncertain As Generic Drug Sales Flounder [Feb-02-22 09:20AM] Novartis Skids After Scrapping An Eczema Drug As Quarterly Metrics Lag [Feb-02-22 11:34AM] Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing [Feb-02-22 10:27AM] Clearview Wealth Advisors LLC Buys Schwab U.S. ... [Feb-02-22 01:38PM]
26-10-2021	PM	5:00 AM ET (Oct 26)	NVS	Novartis AG	189,380	1.71	1.65	1.52	Novartis EPS beats by $0.05, revenue in-line; reaffirms guidance [10/26/2021 1:54 AM]	84.86	1.50 (1.80%)	83.94	0.58 (0.70%)	77.04 - 98.52	3,308,555	1,730,000	98,600
Novartis Q3 2021 Earnings Preview [10/25/2021 2:11 PM] Novartis suffers another setback in Phase 3 study for lung cancer therapy [10/25/2021 6:54 AM] Novartis EPS beats by $0.05, revenue in-line; reaffirms guidance [10/26/2021 1:54 AM] Novartis launches strategic review of generic drugs business Sandoz [10/26/2021 7:09 AM] Novartis posts slowdown in topline growth as Sandoz sales contract in Q3 [10/26/2021 7:37 AM] Here is What Hedge Funds Think About Novartis AG (NVS) [Oct-25-21 09:44AM] Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer [Oct-25-21 01:15AM] Novartis says may divest generic drugs unit Sandoz [Oct-26-21 01:26AM] Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz [Oct-26-21 01:00AM] Novartis may spin off generic unit Sandoz to maximise value [Oct-26-21 01:26AM] Novartis May Spin or Sell Off Ailing Sandoz Generics Unit [Oct-26-21 04:42AM] Novartis May Spin Off or Sell Ailing Sandoz Generics Unit [Oct-26-21 04:42AM] Novartis may divest generic unit Sandoz as price pressures mount [Oct-26-21 01:26AM] Novartis mulls spinning off Sandoz generic drug unit [Oct-26-21 06:34AM] Novartis Starts Review of Generic-Drug Unit [Oct-26-21 07:02AM] Novartis Boosts Guidance For These Key Drugs After Their Bang-Up Quarter [Oct-26-21 08:53AM] The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children [Oct-26-21 08:30AM] Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review [Oct-26-21 09:55AM] Novartis Mulls Selling Underperforming Unit As Sales Decline Continues [Oct-26-21 12:32PM] Novartis (NVS) Q3 2021 Earnings Call Transcript [Oct-26-21 02:00PM]
21-07-2021	PM	0:00 AM ET (Jul 21)	NVS	Novartis AG	203,450	1.64	1.52	1.35	Novartis EPS beats by $0.17, beats on revenue [7/21/2021 1:51 AM]	90.57	0.33 (0.37%)	89.41	-0.83 (-0.92%)	77.04 - 98.52	2,019,842	1,720,000	92,910
Novartis EPS beats by $0.17, beats on revenue [7/21/2021 1:51 AM] Novartis flat despite Q2 earnings beat as CEO sees $10B market for novel cancer therapy [7/21/2021 10:45 AM] Novartis CEO seeing resurgence in non-COVID treatments, lag remains for cancer and heart problems [7/21/2021 4:18 PM] Why Novartis (NVS) Might Surprise This Earnings Season [Jul-20-21 08:38AM] Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity [Jul-20-21 07:05AM] Novartis posts Q2 profit beat, keeps 2021 guidance [Jul-21-21 01:20AM] Novartis profit tops expectations as pandemic impact ebbs [Jul-21-21 01:20AM] Novartis hopes to beat rivals to $10bn cancer treatment market [Jul-20-21 08:00PM] Novartis aims to beat rivals to novel $10bn cancer treatment market [Jul-20-21 08:00PM] Novartis Earnings Top, Drug Giant's Stock Eyes Key Level [Jul-21-21 06:15AM] Novartis Posts Q2 Earnings Beat As Sales Pick Up; Reiterates 2021 Guidance [Jul-21-21 05:07AM] Novartis Earnings Top, Drug Giant's Stock Dips Slightly [Jul-21-21 09:58AM] Novartis Sets 'Positive Tone' For Second-Quarter Pharma, But Stock Falls [Jul-21-21 09:58AM] 'We saw a resurgence in demand in health care systems,' Novartis CEO on Q2 earnings [Jul-21-21 05:04PM] Novartis Sets 'Positive Tone' For Second-Quarter Pharma, Shares Inch Up [Jul-21-21 04:24PM] Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers [Jul-21-21 04:22PM] Novartis (NVS) Q2 2021 Earnings Call Transcript [Jul-21-21 08:31PM]
27-04-2021	PM	5:00 AM ET (Apr 27)	NVS	Novartis AG	199,210	1.52	1.57	1.55	Novartis EPS misses by $0.10, misses on revenue [4/27/2021 2:32 AM]	86.68	-1.13 (-1.29%)	87.18	-0.63 (-0.72%)	77.04 - 98.52	2,779,471	1,900,000	28,801
Novartis Q1 2021 Earnings Preview [4/26/2021 12:33 PM] Novartis EPS misses by $0.10, misses on revenue [4/27/2021 2:32 AM] Novartis Q1 trails estimates; Strong performance across Entresto, Zolgensma, Kymriah sales [4/27/2021 5:46 AM] Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings? [Apr-26-21 11:41AM] Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. [Apr-27-21 01:00AM] Novartis warns of pandemic delay in cancer diagnoses [Apr-26-21 08:00PM] Italy judge sends Bayer, Novartis to trial in drugs fraud probe - sources [Apr-27-21 07:49AM] Novartis Earnings, Sales Slightly Miss Q1 Views [Apr-27-21 08:00AM] Italy judge sends Bayer, Novartis to trial in drugs fraud probe: sources [Apr-27-21 07:53AM] Novartis Earnings, Sales Slightly Miss First-Quarter Views [Apr-27-21 10:26AM] Novartis Q1 Earnings Take A Hit Amid COVID-19 Impact [Apr-27-21 07:45AM] Why Novartis Missed Wall Street Q1 Estimates [Apr-27-21 11:53AM] Novartis Generics Face 'Challenging Quarter,' But Gene Therapy Shines [Apr-27-21 10:26AM] Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes [Apr-27-21 12:47PM] Novartis (NVS) Q1 2021 Earnings Call Transcript [Apr-27-21 01:30PM] ANI Pharmaceuticals, Inc. -- Moody's assigns first-time B2 CFR to ANI Pharmaceuticals; outlook stable [Apr-27-21 01:24PM] Eli Lilly Abandons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease Indications [Apr-27-21 02:34PM]
26-01-2021	PM	5:00 AM ET (Jan 26)	NVS	Novartis AG	220,400	1.34	1.38	1.31	Novartis EPS misses by $0.05, misses on revenue [1/26/2021 4:03 AM]	95.84	-4.09 (-2.67%)	94.58	-3.89 (-3.95%)	69.18 - 99.84	4,097,146	2,157,204	145,165
Novartis EPS misses by $0.05, misses on revenue [1/26/2021 4:03 AM] Novartis Q4 2020 Earnings Preview [1/25/2021 1:33 PM] Novartis down 4% as Q4 trails estimates [1/26/2021 6:37 AM] Novartis proposes dividend raise to CHF 3.00 [1/26/2021 9:13 AM] Novartis CEO says U.S. approval timeline for Leqvio 'out of our control' [Jan-26-21 02:20AM] Novartis's regulatory delays add to pandemic sales hit [Jan-26-21 01:14AM] Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020. [Jan-26-21 01:00AM] Novartis's Earnings Outlook [Jan-25-21 10:24AM]
27-10-2020	PM	5:00 AM ET (Oct 27)	NVS	Novartis AG	193,260	1.52	1.42	1.41	Novartis reports Q3 results, raises FY guidance [10/27/2020 3:06 AM]	80.96	-2.17 (-3.83%)	82.18	-2.00 (-2.38%)	69.18 - 99.84	3,936,094	1,484,739	21,125

21-07-2020	PM	5:00 AM ET (Jul 21)	NVS	Novartis AG	201,790	1.35	1.28	1.32	Novartis EPS beats by $0.03, misses on revenue [7/21/2020 2:27 AM]	86.73	-1.28 (-1.45%)	87.33	-0.68 (-0.77%)	69.18 - 99.84	1,532,801	1,247,441	47,539